论文部分内容阅读
小细胞肺癌在近半个世纪以来,其发病率有逐年增加的趋势,其在全部肺癌中,已从原来仅占肺癌总数的10％发展到现在的30％左右。但就其治疗效果来看,仍不能令人满意。 目前国内外对小细胞肺癌的治疗,虽经多方探索,结合试用各种新疗法、新药物,已使其疗效较过去有所提高,但均不甚满意。当前不论单药化疗或联合化疗,其中位生存期仍大致在25～51周左右。国内单用中药治疗,其平均生存期也仅为14个月左右。
In the past half century, the incidence rate of small cell lung cancer has increased year by year. It has grown from only 10% of the total number of lung cancers to about 30% of the current total in all lung cancers. However, in terms of its therapeutic effect, it is still not satisfactory. At present, the treatment of small cell lung cancer at home and abroad, despite many explorations, combined with trials of various new therapies and new drugs, has made its efficacy more efficient than in the past, but it is not satisfactory. Currently, whether single-agent chemotherapy or combination chemotherapy, the median survival time is still about 25 to 51 weeks. Domestic single Chinese medicine treatment, the average survival time is only about 14 months.